I-Mab (IMAB) News Today $0.98 +0.01 (+1.07%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$0.98 0.00 (0.00%) As of 02/21/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period I-Mab (NASDAQ:IMAB) Shares Down 0.3% - Here's WhyI-Mab (NASDAQ:IMAB) Stock Price Down 0.3% - Should You Sell?February 22 at 12:49 AM | marketbeat.comI-Mab management to meet virtually with BTIGFebruary 20 at 2:48 PM | markets.businessinsider.comI-Mab to Participate in Leerink Partners Global Healthcare ConferenceFebruary 18, 2025 | globenewswire.comI-Mab to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences ConferenceFebruary 5, 2025 | markets.businessinsider.comI-Mab to Present at Oppenheimer's 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | globenewswire.comI-Mab (NASDAQ:IMAB) Short Interest Up 31.9% in JanuaryI-Mab (NASDAQ:IMAB - Get Free Report) was the recipient of a large growth in short interest in January. As of January 15th, there was short interest totalling 904,000 shares, a growth of 31.9% from the December 31st total of 685,600 shares. Based on an average daily trading volume, of 477,100 shares, the short-interest ratio is presently 1.9 days.January 31, 2025 | marketbeat.comI-Mab (NASDAQ:IMAB) Sees Large Increase in Short InterestI-Mab (NASDAQ:IMAB - Get Free Report) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 904,000 shares, a growth of 31.9% from the December 15th total of 685,600 shares. Based on an average daily volume of 477,100 shares, the short-interest ratio is currently 1.9 days.January 18, 2025 | marketbeat.comI-Mab Maintains Buy Rating Amid Strategic Refocus on Givastomig and Financial StabilityJanuary 9, 2025 | markets.businessinsider.comI-Mab announces open market purchases of ADSs by board memberJanuary 8, 2025 | markets.businessinsider.comI-Mab Board Chairman to Acquire $2 Million in ADSsJanuary 8, 2025 | markets.businessinsider.comI-Mab Chairman plans $2 million ADS purchaseJanuary 8, 2025 | investing.comI-Mab Announces Open Market Purchases of Company American Depositary Shares by Board MemberJanuary 8, 2025 | prnewswire.comI-Mab pauses CD73 antibody development in pipeline reshuffleJanuary 7, 2025 | finance.yahoo.comI-Mab stock jumps 15% following pipeline updateJanuary 6, 2025 | msn.comI-Mab Announces Portfolio Prioritization of Givastomig (CLDN18. ...January 6, 2025 | gurufocus.comI-Mab Prioritizes Givastomig as Lead Program in Strategic ShiftJanuary 6, 2025 | tipranks.comI-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical ProgramJanuary 6, 2025 | prnewswire.comI-Mab (NASDAQ:IMAB) Short Interest Up 13.5% in DecemberI-Mab (NASDAQ:IMAB - Get Free Report) saw a large increase in short interest in December. As of December 15th, there was short interest totalling 685,600 shares, an increase of 13.5% from the November 30th total of 604,100 shares. Based on an average trading volume of 469,300 shares, the days-to-cover ratio is presently 1.5 days.January 1, 2025 | marketbeat.comI-Mab Leads Our Spotlight On 3 US Penny StocksDecember 4, 2024 | finance.yahoo.comI-Mab Biopharma’s Strategic Shift to US-Based BiotechDecember 4, 2024 | markets.businessinsider.comI-Mab to Participate at the Piper Sandler Healthcare ConferenceNovember 21, 2024 | prnewswire.comI-Mab’s Third Quarter Results: Progress in Cancer ImmunotherapiesNovember 16, 2024 | tipranks.comI-MAB Receives Buy Rating as Uliledlimab and Givastomig Show Promising Clinical ProgressNovember 15, 2024 | markets.businessinsider.comI-Mab (NASDAQ:IMAB) Earns "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $8.00 price objective on shares of I-Mab in a research report on Friday.November 15, 2024 | marketbeat.comI-Mab Biopharma: I-Mab Reports Third Quarter 2024 ResultsNovember 15, 2024 | finanznachrichten.deI-Mab’s Promising Q3 Results and Strategic MovesNovember 14, 2024 | markets.businessinsider.comI-Mab Reports Third Quarter 2024 ResultsNovember 14, 2024 | prnewswire.comI-Mab (IMAB) Scheduled to Post Quarterly Earnings on ThursdayI-Mab (NASDAQ:IMAB) will be releasing earnings before the market opens on Thursday, November 14, Zacks reports.November 7, 2024 | marketbeat.comI-Mab (IMAB) Set to Announce Quarterly Earnings on ThursdayI-Mab (NASDAQ:IMAB) will be releasing earnings before the market opens on Thursday, November 14, Zacks reports.November 7, 2024 | marketbeat.comI-Mab Appoints New CEO to Drive Cancer Therapy GoalsNovember 7, 2024 | markets.businessinsider.comI-Mab names Sean Fu as permanent CEONovember 7, 2024 | markets.businessinsider.comInhibrx prevails in trade secret case with I-MabNovember 6, 2024 | markets.businessinsider.comI-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive OfficerNovember 6, 2024 | prnewswire.comI-Mab to Release Q3 2024 Financial Results on November 14, 2024October 31, 2024 | prnewswire.comI-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024October 30, 2024 | prnewswire.comI-Mab to Participate at the Truist Securities BioPharma SymposiumOctober 28, 2024 | prnewswire.comI-Mab Biopharma’s Strategic US Transition and Pipeline FocusOctober 25, 2024 | finance.yahoo.comI-Mab (IMAB) Latest Stock News & Headlines - Yahoo FinanceSeptember 20, 2024 | ca.finance.yahoo.comI-Mab (NASDAQ:IMAB) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and issued a $8.00 price objective on shares of I-Mab in a report on Tuesday.September 17, 2024 | marketbeat.comI-Mab Reports Promising Results From Phase 1 Study Of Givastomig In Gastric CancerSeptember 17, 2024 | markets.businessinsider.comI-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024September 16, 2024 | prnewswire.comI-Mab (NASDAQ:IMAB) Sees Large Decrease in Short InterestI-Mab (NASDAQ:IMAB - Get Free Report) saw a significant decrease in short interest during the month of August. As of August 31st, there was short interest totalling 716,600 shares, a decrease of 15.9% from the August 15th total of 852,300 shares. Based on an average daily volume of 191,400 shares, the short-interest ratio is currently 3.7 days.September 16, 2024 | marketbeat.comI-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung CancerSeptember 10, 2024 | prnewswire.comI-Mab (NASDAQ:IMAB) Short Interest Down 8.2% in AugustI-Mab (NASDAQ:IMAB - Get Free Report) was the recipient of a significant decline in short interest in August. As of August 15th, there was short interest totalling 852,300 shares, a decline of 8.2% from the July 31st total of 928,300 shares. Based on an average trading volume of 236,900 shares, the days-to-cover ratio is currently 3.6 days.September 2, 2024 | marketbeat.comFY2024 EPS Estimates for I-Mab (NASDAQ:IMAB) Boosted by AnalystI-Mab (NASDAQ:IMAB - Free Report) - Analysts at HC Wainwright upped their FY2024 earnings per share estimates for shares of I-Mab in a research report issued on Thursday, August 29th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($0.09) per share for the year, up from thSeptember 2, 2024 | marketbeat.comI-MAB (IMAB) Q2 2024 Earnings Call TranscriptAugust 29, 2024 | seekingalpha.comI-MAB (NASDAQ:IMAB) Stock Quotes, Forecast and News SummaryAugust 29, 2024 | benzinga.comI-Mab (NASDAQ:IMAB) Q2 2024 Earnings Call TranscriptAugust 29, 2024 | msn.comI-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business UpdatesAugust 28, 2024 | prnewswire.comI-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 26, 2024 | prnewswire.com Get I-Mab News Delivered to You Automatically Sign up to receive the latest news and ratings for IMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address IMAB Media Mentions By Week IMAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMAB News Sentiment▼0.220.60▲Average Medical News Sentiment IMAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMAB Articles This Week▼31▲IMAB Articles Average Week Get I-Mab News Delivered to You Automatically Sign up to receive the latest news and ratings for IMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Corvus Pharmaceuticals News Trevi Therapeutics News COMPASS Pathways News Aquestive Therapeutics News Gossamer Bio News Candel Therapeutics News Atyr PHARMA News Immutep News Olema Pharmaceuticals News Korro Bio News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMAB) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding I-Mab Please log in to your account or sign up in order to add this asset to your watchlist. Share I-Mab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMAB Stock Alerts